Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait

R Alroughani 1, J Al Hashel, A Thussu, S F Ahmed

Affiliations

01 January 2013

-

doi: 10.1159/000351568

Abstract

Objective: To evaluate the outcomes of patients with multiple sclerosis (MS) who were treated with natalizumab in Kuwait.

Materials and methods: A retrospective study using the MS registry to identify patients who were treated with natalizumab was conducted. Patients' demographics, clinical characteristics and treatment parameters were collected at baseline and last follow-up visit. Primary outcome was the proportion of relapse-free patients at the last follow-up while secondary outcomes were the change in the mean annual relapse rate, Expanded Disability Status Scale (EDSS) and the proportion of patients with magnetic resonance imaging (MRI) activity at the last follow-up visit. Forty-four patients were included in the study.

Results: Of the 44 patients, 27 (61.4%) were females and the remaining 17 (38.6%) males. Mean age of patients and mean disease duration were 29.05 ± 7.25 and 5.71 ± 3.37 years, respectively. The mean number of natalizumab infusions was 18.14. The proportion of relapse-free patients significantly increased from 11.36 to 90.91% (p < 0.0001). The EDSS significantly improved from 4.76 to 3.15 (p < 0.0001) over the observational period. There was no significant difference between patients with EDSS <3 compared to those with EDSS ≥ 3 (p < 0.67). The proportion of patients with MRI activity was significantly reduced from 95.5 to 18.2% (p < 0.0001) at their last visit. Six patients discontinued the drug, 5 due to positive JC virus and 1 due to pregnancy.

Conclusions: Natalizumab induced a suppression of disease activity and was responsible for a significant improvement in disability status in highly active MS patients.

Similar articles

The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.

Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.Pediatr Neurol. 2017 May;70:56-60. doi: 10.1016/j.pediatrneurol.2017.01.017. Epub 2017 Feb 2.PMID: 28389054

Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.

Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.Curr Med Res Opin. 2014 Sep;30(9):1849-55. doi: 10.1185/03007995.2014.921144. Epub 2014 May 28.PMID: 24831186

Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.

Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.Eur Neurol. 2014;72(3-4):173-80. doi: 10.1159/000361044. Epub 2014 Sep 6.PMID: 25226868

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.Cochrane Database Syst Rev. 2013 Jun 6;(6):CD008933. doi: 10.1002/14651858.CD008933.pub2.PMID: 23744561 Review.

[Natalizumab as induction therapy in multiple sclerosis].

Corlobé A, Charif M, Mania A, Outteryck O, de Sèze J, Labauge P.Rev Neurol (Paris). 2014 Jan;170(1):2-5. doi: 10.1016/j.neurol.2013.06.004. Epub 2013 Oct 11.PMID: 24125463 Review. French.

Cited by

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile.

Ysrraelit MC, Caride A, Sinay V, Rivera Kindel M, Halfon MJ, Patrucco L, Piedrabuena R, Diaz Aragunde VE.Arq Neuropsiquiatr. 2021 May;79(5):407-414. doi: 10.1590/0004-282X-ANP-2020-0303.PMID: 34161529 Free PMC article.

Differentiation of Cognitive Deficit Profiles in Multiple Sclerosis Patients: Latent Profile Analysis.

Slavković S, Lazić M, Honan C, Nađ Č, Brkić-Jovanović N, Golubović Š.Med Princ Pract. 2019;28(4):373-379. doi: 10.1159/000499312. Epub 2019 Mar 4.PMID: 30831571 Free PMC article.

Expanded Disability Status Scale-Based Disability and Dental-Periodontal Conditions in Patients with Multiple Sclerosis.

Hatipoglu H, Canbaz Kabay S, Gungor Hatipoglu M, Ozden H.Med Princ Pract. 2016;25(1):49-55. doi: 10.1159/000440980. Epub 2015 Oct 17.PMID: 26473494 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg. 2006;108:327–332. - PubMed
  2.  
    1. Disanto G, Morahan JM, Ramagopalan SV. Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Drug Targets. 2012;1:545–555. - PubMed
  3.  
    1. Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol. 2012;25:246–251. - PMC - PubMed
  4.  
    1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. - PubMed
  5.  
    1. Rudick RA, Stuart WH, Calabresi PA, et al. for the SENTINEL Investigators Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–923. - PubMed
  6.  
    1. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 1992;356:63–66. - PubMed
  7.  
    1. Prosperini L, Giannì C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler. 2012;18:64–71. - PubMed
  8.  
    1. Lanzillo R, Quarantelli M, Bonavita S, et al. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand. 2012;126:306–314. - PubMed
  9.  
    1. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–374. - PubMed
  10.  
    1. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med. 2005;353:414–416. - PubMed
  11.  
    1. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. - PubMed
  12.  
    1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415. - PubMed
  13.  
    1. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double blind, randomized, placebo-controlled FREEDOMS study. Lancet Neurol. 2012;11:420–428. - PubMed
  14.  
    1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol. 2005;58:840–846. - PubMed
  15.  
    1. Vercellino M, Romagnolo A, Mattioda A, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand. 2009;119:126–130. - PubMed
  16.  
    1. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1528–1532. - PubMed
  17.  
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33:1444–1452. - PubMed
  18.  
    1. Prosperini L, Giannì C, Barletta V, et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci. 2012;323:104–112. - PubMed
  19.  
    1. Kallweit U, Jelcic I, Braun N, et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol. 2012;35:77–80. - PubMed
  20.  
    1. Oturai AB, Koch-Henriksen N, Petersen T, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009;16:420–423. - PubMed
  21.  
    1. Putzki N, Yaldizli O, Bühler R, et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol. 2010;63:101–106. - PubMed
  22.  
    1. Putzki N, Kollia K, Woods S, et al. Natalizumab is effective as second-line therapy in the treatment of relapsing remitting MS. Eur J Neurol. 2009;16:424–426. - PubMed
  23.  
    1. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405–415. - PubMed
  24.  
    1. Degenhardt A, Ramagopalan SV, Scalfari A, et al. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol. 2009;5:672–682. - PubMed
  25.  
    1. Tremlett H, Zhao Y, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14:314–324. - PubMed
  26.  
    1. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004;56:303–306. - PubMed
  27.  
    1. Fernández O, Oreja-Guevara C, Arroyo R, et al. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol. 2012;259:1814–1823. - PMC - PubMed
  28.  
    1. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260. - PubMed
  29.  
    1. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78:1736–1742. - PubMed
  30.  
    1. Warnke C, Dehmel T, Posevitz-Fejfár A, et al. Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler. 2012;18:1054–1055. - PubMed

Page Navigation